Dr Brown on the NCCN Guideline Inclusion of Brigatinib for NF2-Related Schwannomatosis
Rebecca Brown, MD, discusses how the NCCN guideline inclusion of brigatinib is changing clinical practice for NF2-related schwannomatosis.
Rebecca Brown, MD, discusses how the NCCN guideline inclusion of brigatinib is changing clinical practice for NF2-related schwannomatosis.
Original Source: NewsData.io Business & Tech Wire
Comments (0)
No comments yet. Be the first to share your thoughts!
Leave a Comment